Meng Lingjun, Jin Wei, Wang Yuhui, Huang Huanwei, Li Jia, Zhang Cai
College of Biological Sciences, China Agricultural University, Beijing 100094, China; National Institute of Biological Sciences, Beijing 102206, China.
Institute for Immunology, Tsinghua University, Beijing 100084, China.
Biochem Biophys Res Commun. 2016 Apr 29;473(2):497-502. doi: 10.1016/j.bbrc.2016.03.059. Epub 2016 Mar 17.
Atherothrombotic vascular disease is already the leading cause of mortality worldwide. Atherosclerosis shares features with diseases caused by chronic inflammation. More attention should concentrates on the innate immunity effect atherosclerosis progress. RIP3 (receptor-interacting protein kinase 3) act through the transcription factor named Nr4a3 (Nuclear orphan receptors) to regulate cytokine production. Deletion RIP3 decreases IL-1α production. Injection of anti-IL-1α antibody protects against the progress of atherosclerosis in ApoE -/- mice. RIP3 as a molecular switch in necrosis, controls macrophage necrotic death caused inflammation. Inhibiting necrosis will certainly reduce atherosclerosis through limit inflammation. Necrotic cell death caused systemic inflammation exacerbated cardiovascular disease. Inhibition of necrosis may yield novel therapeutic targets for treatment in years to come.
动脉粥样硬化血栓形成性血管疾病已经是全球范围内主要的死亡原因。动脉粥样硬化与由慢性炎症引起的疾病有共同特征。应更多关注先天免疫对动脉粥样硬化进展的影响。RIP3(受体相互作用蛋白激酶3)通过名为Nr4a3(核孤儿受体)的转录因子发挥作用,以调节细胞因子的产生。缺失RIP3会降低IL-1α的产生。注射抗IL-1α抗体可预防ApoE -/-小鼠动脉粥样硬化的进展。RIP3作为坏死中的分子开关,控制巨噬细胞坏死性死亡引起的炎症。抑制坏死肯定会通过限制炎症来减轻动脉粥样硬化。坏死性细胞死亡引起的全身炎症会加剧心血管疾病。抑制坏死可能会在未来几年产生新的治疗靶点。